With regards to ICI therapy, a study with 46 melanoma patients treated with Nivolumab (anti–PD-1 Ab) showed a significant increase in the frequency of Th9 cells in the peripheral blood of those patients that responded to the therapy, while other Th subsets remained unchanged between responders and non-responders (66). Here, PDCD1 is linked to melanoma.